Respiratory Season 21

Meet the challenges that this respiratory season will bring

As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems (1–3).

Diagnostic approaches using rapid molecular testing may help alleviate this burden (4,5). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.

Detection of emerging SARS-CoV-2 Delta, Mu and Omicron variants

The QIAstat-Dx Respiratory SARS-CoV-2 Panel remains capable of detecting SARS-CoV-2 infections in light of the emergence of new coronavirus variants, including Omicron (B.1.1.529).

LEARN MORE

Illustration of the Coronavirus, schematic drawing of the virus

Adopting a syndromic diagnostic approach to serve the community during COVID-19

When COVID-19 struck in Northwest Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. She placed her trust in the QIAstat-Dx system to test for a wide range of pathogens, not just SARS-CoV-2, to help provide fast answers and peace of mind to her community.

read her story

Featured
–
explore syndromic respiratory testing

Confronting emerging COVID-19 variants
Over the course of the COVID-19 pandemic, data on novel SARS-CoV-2 variants with potentially increased transmissibility has continued to evolve Stay up to date on our continuous surveillance assessing the impact of mutations on assay sensitivity. (Updated September 2021)
READ THE REPORT
COVID-19 and co-infection – what do we know?
Sometimes, testing for SARS-CoV-2 is not enough. A 30-study systematic review and meta-analysis published in the Journal of Infection suggests that some COVID-19 patients may be infected by more than one pathogen
READ STUDY HIGHLIGHTS
Multiple benefits to syndromic testing
Traditional diagnostic methods, such as bacterial culture and microscopy, can take too long or are not sensitive enough. View our infographic to see how the benefits of syndromic testing go beyond improved patient care and extend throughout your hospital system.
VIEW INFOGRAPHIC

Don’t just test for SARS-CoV-2 this season

In this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero discusses the role of syndromic testing during the ongoing COVID-19 pandemic. He also addresses the importance of time to diagnosis and potential for co-infections during respiratory season.

WATCH NOW

Don’t just test for SARS-CoV-2 this season

Uniquely powerful
–
our solution for syndromic testing

Comprehensive pathogen identification
The QIAstat-Dx Respiratory SARS-CoV-2 Panel offers:
- Detection of 22 respiratory targets, including SARS-CoV-2
- Comprehensive results in around 1 hour
Ct values and amplification curves
The QIAstat-Dx System provides additional information that may help support diagnostic decision making:
- Ct values
- Amplification curves
Powerful connectivity features
Connection with the QIAsphere app provides*:
- QIAstat-Dx Analyzer status updates – anytime, anywhere
- Remote and proactive technical support
- On-demand epidemiological reports

* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 22 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Download the flyer

icon-callout-help

Ready to learn how syndromic testing with QIAstat-Dx can benefit your institution?

Contact an expert

Additional resources

COVID-19 solutions and resources
Learn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
Find solutions
Verification guidelines for our respiratory assay
In this application note, read a sample protocol for verifying the performance of the QIAstat-Dx Respiratory SARS-CoV-2 Panel in your laboratory.
Read the protocol
The benefits of syndromic testing extend beyond the pandemic
The team at Mako Medical in North Carolina, USA, recognizes senior living communities are especially vulnerable to disease outbreaks. Syndromic testing is used at this lab to ensure fast results.
Read their story
QIAstat-Dx reporting at your fingertips
Get complete visibility of QIAstat-Dx instrument status across your institute with push notifications in the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide.
Get the guide

*Some features require a QIAstat-Dx Connectivity plan; flexible plans are available to meet your lab’s needs

References

Hodjat, P., Christensen, P.A., Subedi, S., Bernard, D.W., Olsen, R.J. and Long, S.W. (2021) The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. medRxiv. doi: https://doi.org/10.1101/2021.05.27.21257940
Centers for Disease Control and Prevention Weekly U.S. Influenza Surveillance Report https://www.cdc.gov/flu/weekly/index.htm
Centers for Disease Control and Prevention Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States https://emergency.cdc.gov/han/2021/han00443.asp
European Centre for Disease Prevention and Control COVID-19 testing strategies and objectives https://www.ecdc.europa.eu/sites/default/files/documents/TestingStrategy_Objective-Sept-2020.pdf
Centers for Disease Control and Prevention Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.

Preparing for an uncertain respiratory season